Kernal Biologics

We're thrilled to be presenting new data from our mRNA 2.0 platform at the @ASGCTherapy Annual Meeting in Boston:  businesswire.com/news/home/2026…

We’re honored to share that Advanced Research Projects Agency for Health (@ARPA_H) has awarded us up to $48 million to accelerate our in vivo CAR-T therapies toward the clinic. #invivoCART #biotech #geneticmedicine Read the full announcement👉. . businesswire.com/news/home/2025…

🚀Big news from Kernal Bio! We’re thrilled to share that @kernalbio has joined Lilly Gateway Labs—a premier innovation accelerator housed within @EliLillyandCo's Seaport Innovation Center in #Boston. #invivoCART #mRNA2point0 #LLM #kernaLM #biotech #celltherapy

There’s nothing like the beautiful @LabCentral in Kendall Square Cambridge where the awesome @kernalbio team is combining AI + mRNA + LNP to create new and better medicines. @CivilizationVC seeded.

In addition, Cafer Ozdemir, PhD, Co-founder of Kernal Bio, will be giving a talk at the 14th #mrnaconference about the company and showcasing our computational platform for cell-selective mRNA designs. He'll also present his poster on Tuesday, Nov. 12! #mRNA

Manfred Kraus, Ph.D., Sr. V.P. of R&D at @kernalbio will presenting our in vivo CAR-T approach for potential uses in blood cancers and autoimmune disorders. Don’t miss his presentation at the 14th @mrnaconference on Tuesday, Nov. 12 in Boston! #mrna

Busy afternoon sessions with @BeaconIntel @LumaCyte & @kernalbio! #CARTCR

Photo credit to our SAB member, Prof. Dan Peer @peer_lab.

Cafer Ozdemir, PhD, Co-founder of Kernal Bio, gave a great presentation today at the 11th International @mrnaconference in Berlin, Germany. The title of his talk was "Engineering Synthetic #mRNAs That Are Selectively Translated In Cancer Cells."

Kernal Bio to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting! KR-336 Data Support Use of #Oncoselective mRNA LNPs as a Novel, Promising Modality for #Systemic Immuno-oncology Applications prnewswire.com/news-releases/… @mRNA @cancer @sitcancer #sitc23

Join us at the 3rd mRNA-based Therapeutics Summit!

Kernal Biologics to Present at 3rd Annual mRNA-Based Therapeutics Summit lnkd.in/eaCqNuHw

@yusuf_erkul, M.D., Co-founder and CEO of Kernal Bio, will moderate both morning and afternoon Translation sessions on Friday, July 28.

Manfred Kraus, Ph.D., Head of Research & Development, will showcase KR-335 and KR-336 programs that have shown robust efficacy across IO-resistant tumor models.

We’re incredibly excited to publish the inaugural edition of the Decoding Bio Snapshot. Several months in the making, it profiles 40 companies operating at the intersection of computation and biology, ranging from pre-seed to publicly traded. snapshot.decodingbio.com

Join us at #bio2023 ! Our CEO @yusuf_erkul will be presenting on Tue, June 6 at 4:30 PM, Room 103 at the @IAmBiotech BIO International Convention. #mRNA

Kernal Biologics to Present at Locust Walk RNA Innovation Conference #mrna #cancer #mrna2point0 Locust Walk prnewswire.com/news-releases/…

Kernal Bio's #oncoselective mRNA tech is featured on @statnews with a quote from our CEO: "I’ve been watching this field very closely from before our conception,” said Erkul. “I haven’t seen anything like this in terms of onco-selectivity. This is as exciting as it gets."

We are looking forward to presenting our platform capabilities next week at the 2nd Annual #mRNATherapeuticsSummit. For more information about the event: ter.li/otpu4f #Oncology #mRNA

Congrats to the team @kernalbio! Kernal Bio (YC S20) uses proprietary mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease — while eliminating as many common side effects as possible: fiercebiotech.com/biotech/amgen-…